SEC Form 8-K Summary
Issuer: Eliem Therapeutics, Inc. The request identifies Climb Bio, Inc., but the filing names Eliem Therapeutics, Inc. as the registrant.
Reporting date: December 14, 2022; filed December 20, 2022. The filing reports executive compensation matters under Item 5.02.
Business Context and Reporting Period
The filing concerns 2022 performance bonus determinations and 2023 executive compensation arrangements. It does not provide operating or financial results for a quarterly or annual reporting period.
Key Financial and Compensation Metrics
| Executive | 2022 Performance Bonus | 2023 Base Salary | 2023 Target Bonus |
|---|---|---|---|
| Robert Azelby, President and CEO | $438,750 | $702,000 | 65% of base salary |
| Erin M. Lavelle, COO/CFO | $209,588 | $484,380 | 45% of base salary |
| Valerie Morisset, Ph.D., EVP R&D and CSO | £145,467 | £336,190 | 45% of base salary |
The filing text does not provide revenue, profit, cash flow, margins, debt, liquidity, share-price, or other operating metrics. The currency shown for Dr. Morisset’s compensation is pounds sterling in the filing text.
Material Changes Versus Prior Comparable Period
No prior-period compensation amounts or percentage changes are provided. The Committee approved 2023 salaries and target bonus percentages, but the filing does not quantify year-over-year changes.
Guidance, Outlook, Risks, and Unusual Items
- 2023 bonuses will be based on Company performance goals and, for executives other than Mr. Azelby, individual performance goals.
- Mr. Azelby’s 2023 bonus will be based solely on Company performance goals.
- The Board had not yet established the 2023 Company performance goals as of the filing date.
- Individual performance goals will involve a subjective assessment of each executive’s contributions.
- The 2022 bonuses were determined after the Compensation Committee reviewed Company and individual performance goals and other relevant factors, and were to be paid in 2023.
- No material litigation, contingency, liquidity issue, or business outlook was disclosed.
Investor Verification Checklist
- Verify the issuer identity because the provided request names Climb Bio, Inc., while the filing names Eliem Therapeutics, Inc.
- Confirm the currency and amounts for Valerie Morisset’s compensation, which are displayed in pounds sterling in the source text.
- Review the company’s proxy statement for additional compensation factors and disclosures.
- Monitor later filings for the Board’s 2023 Company performance goals and any subsequent changes to executive compensation.